About us

Gate2Brain is an early-stage biotech company launched to improve drug delivery across biological barriers through the use of a radically innovative peptide-based patented technology.

Our lead asset (G2B-001) is a first-in-class therapeutic approach for solid tumors presenting harsh barriers to anticancer drug delivery. 

We focus on pediatric diseases such as Diffuse Intrinsic Pontine Glioma (DIPG).